Study of MDX-1411 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma (MDX1411-02)

Bristol-Myers Squibb (BMS)

Status and phase: Withdrawn; Phase 1

Conditions: Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma.

Treatments: Biological: MDX-1411

Study type: Interventional

Funder types: Industry

Identifiers

NCT00730652

MDX1411-02

Details and patient eligibility

About

To determine if MDX-1411 is safe for the treatment of chronic lymphocytic leukemia or mantle cell lymphoma.

Full description

Dose-escalation, multidose study of MDX-1411, a fully human nonfucosylated monoclonal antibody (mAb) targeting the CD70 transmembrane cell-surface protein, which is highly expressed in B-cell malignancies such as CLL and MCL.

Enrollment: 34 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically confirmed diagnosis of relapsed/refractory MCL or hematologically/bone marrow confirmed relapsed/refractory CLL that is not amenable to cure by surgery or other means and has failed at least 1 prior systemic therapy;
• Subjects may have been treated with up to 6 prior systemic therapies for relapsed/refractory disease or have become intolerant to a systemic therapy
• For MCL, must have measurable disease
• At least 4 weeks since the last systemic therapy, including RT, for the treatment of MCL/CLL;
• At least 4 weeks since taking any corticosteroids prior to the first dose of MDX-1411
• ECOG Performance Status 0 to 2;
• No known positivity for human immunodeficiency virus (HIV) and no active infection with Hepatitis B or Hepatitis C;

Exclusion criteria

• History of severe hypersensitivity reactions to other monoclonal antibodies;
• Use of other investigational drugs within 30 days before study drug administration
• Prior treatment with any other anti-CD70 antibody;
• Active infection requiring i.v. systemic therapy within 4 weeks of receiving the first dose of MDX-1411;
• Evidence of bleeding diathesis or coagulopathy;
• Active autoimmune disease requiring immunosuppressive therapy;
• Known current drug or alcohol abuse;
• Underlying medical conditions that will make the administration of MDX-1411 hazardous

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

34 participants in 1 patient group

MDX1411

Experimental group

Description:

An accelerated titration design (ATD) will be utilized and subjects will be assigned to a dose level in the order they enter the study.

Treatment:

Biological: MDX-1411